Bertilimumab is a first-in-class human monoclonal antibody that targets and lowers eotaxin-1 levels. Eotaxin-1 is a chemokine that attracts eosiniphils to sites of inflamation - thus by blocking eotaxin-1, bertilimumab may reduce eosinophil migration or activation and thus provide a benefit to patients suffering from a variety of immunologic and inflammatory diseases. To date, bertilimumab has been well tolerated, with over 100 subjects having received bertilimumab in clinical trials, and has shown promising signs of activity in patients with moderate-to-severe bullous pemphigoid, a rare skin blistering disease. Read More 

Latest News

PRESS RELEASE July 17, 2018

Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split | Read more 


PRESS RELEASE July 9, 2018

WuXi Biologics and Immune Pharmaceuticals Announce Late-phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody | Read more 


PRESS RELEASE June 8, 2018

Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events